Expanded access programme of nivolumab in Italian patients with stage IIIB/stage IV Non-small-cell-lung-cancer: data from a real world setting

Trial Profile

Expanded access programme of nivolumab in Italian patients with stage IIIB/stage IV Non-small-cell-lung-cancer: data from a real world setting

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Results assessing efficacy and safety of nivolumab in elderly patients (greater than or equal to 75 years) (n=70) presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Preliminary efficacy and safety results (n=38) in NSCLC patients with brain metastasis were presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Preliminary efficacy and safety results in never smoker patients (n=38) were presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top